Gastroenteritis - Pipeline Review, H1 2018

  • ID: 4515977
  • Drug Pipelines
  • 66 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Kyowa Hakko Kirin Co Ltd
  • Ology Bioservices Inc
  • RedHill Biopharma Ltd
  • Vaxart Inc
  • MORE
Gastroenteritis - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Gastroenteritis - Pipeline Review, H1 2018, provides an overview of the Gastroenteritis (Gastrointestinal) pipeline landscape.

Gastroenteritis is an infection of the gut. Symptoms include stomach pain, cramping, fever, nausea, and a headache. Causes of gastroenteritis include contaminated food or water, and contact with someone who has the virus. Treatment includes antibiotics, anti-emetic and anti-diarrheal medications.

Report Highlights:

This latest Pharmaceutical and Healthcare disease pipeline guide pipeline guide Gastroenteritis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Gastroenteritis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastroenteritis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Gastroenteritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Gastroenteritis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researechers' proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gastroenteritis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Gastroenteritis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gastroenteritis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gastroenteritis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gastroenteritis (Gastrointestinal)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gastroenteritis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gastroenteritis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Kyowa Hakko Kirin Co Ltd
  • Ology Bioservices Inc
  • RedHill Biopharma Ltd
  • Vaxart Inc
  • MORE
Introduction

Report Coverage

Gastroenteritis - Overview

Gastroenteritis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Gastroenteritis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Gastroenteritis - Companies Involved in Therapeutics Development

Kyowa Hakko Kirin Co Ltd

Ology Bioservices Inc

RedHill Biopharma Ltd

Takeda Pharmaceutical Co Ltd

Vaxart Inc

Gastroenteritis - Drug Profiles

AK-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibodies for Gastroenteritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibodies to Target TRIM-21 for Gastrointestinal and Ear Nose Throat Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

benralizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Norovirus (bivalent, virus like particle) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ondansetron hydrochloride CR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-214 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VXAG-1.1NN - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gastroenteritis - Dormant Projects

Gastroenteritis - Discontinued Products

Gastroenteritis - Product Development Milestones

Featured News & Press Releases

Mar 27, 2018 : RedHill Biopharma Announces Two Oral Presentations on BEKINDA 24 mg for acute gastroenteritis at the SAEM 2018 Annual Meeting

Mar 02, 2018 : Vaxart to Present Clinical Data From Oral Norovirus Vaccine Program at International Congress on Infectious Diseases

Oct 30, 2017: Vaxart Announces Positive Safety and Immunogenicity Results for Its Oral Norovirus Vaccine in a Phase 1b Clinical Study

Jun 19, 2017: RedHill Biopharma to Host Conference Call on Successful Phase III Top-Line Results with BEKINDA for Acute Gastroenteritis

Jun 14, 2017: RedHill Biopharma Announces Successful Phase III Top-Line Results with BEKINDA for Acute Gastroenteritis

Apr 19, 2017: RedHill Biopharma to Host R&D Day on BEKINDA for Acute Gastroenteritis and IBS-D

Apr 18, 2017: RedHill Biopharma Receives Notice of Allowance for Two Additional U.S. Patents Covering BEKINDA

Feb 21, 2017: RedHill Biopharma Completes Treatment of Last Patient in BEKINDA Phase III Study for Acute Gastroenteritis

Feb 13, 2017: RedHill Biopharma Announces Enrollment of Last Patient in BEKINDA Phase III Study for Acute Gastroenteritis

Jan 12, 2017: RedHill Biopharma Provides Milestone Update on Bekinda

Nov 03, 2016: RedHill Biopharma Provides Update on Ongoing Phase III and Phase II studies with BEKINDA and Expected Timing of Top-Line Results

Jun 20, 2016: Takeda Initiates Worlds First Norovirus Vaccine Field Trial

Mar 01, 2016: RedHill Biopharma Provides Update on RHB-

Nov 10, 2015: Vaxart Presents Positive Preclinical Data for Its Oral Norovirus Vaccine at the 16th Annual World Vaccine Congress in Madrid

Oct 14, 2015: RedHill Biopharma Provides Update on BEKINDA Ongoing Phase III Study for Gastroenteritis and Announces Planned Phase II Study for IBS-D

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Gastroenteritis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Gastroenteritis - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2018

Gastroenteritis - Pipeline by Ology Bioservices Inc, H1 2018

Gastroenteritis - Pipeline by RedHill Biopharma Ltd, H1 2018

Gastroenteritis - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018

Gastroenteritis - Pipeline by Vaxart Inc, H1 2018

Gastroenteritis - Dormant Projects, H1 2018

Gastroenteritis - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Gastroenteritis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Kyowa Hakko Kirin Co Ltd
  • Ology Bioservices Inc
  • RedHill Biopharma Ltd
  • Takeda Pharmaceutical Co Ltd
  • Vaxart Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll